BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: England RM, Hare JI, Barnes J, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, Ashford MB. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. Journal of Controlled Release 2017;247:73-85. [DOI: 10.1016/j.jconrel.2016.12.034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Rai DB, Medicherla K, Pooja D, Kulhari H. Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment. Pharmaceutics 2023;15:801. [DOI: 10.3390/pharmaceutics15030801] [Reference Citation Analysis]
2 Gogoi P, Kaur G, Singh NK. Nanotechnology for colorectal cancer detection and treatment. World J Gastroenterol 2022; 28(46): 6497-6511 [DOI: 10.3748/wjg.v28.i46.6497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Younis NK, Roumieh R, Bassil EP, Ghoubaira JA, Kobeissy F, Eid AH. Nanoparticles: attractive tools to treat colorectal cancer. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hani U, Honnavalli YK, Begum MY, Yasmin S, Osmani RAM, Ansari MY. Colorectal cancer: A comprehensive review based on the novel drug delivery systems approach and its management. Journal of Drug Delivery Science and Technology 2021;63:102532. [DOI: 10.1016/j.jddst.2021.102532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen J, Zhou L, Wang C, Sun Y, Lu Y, Li R, Hu X, Chen M, Chen L, Chai K, Yao T, Shi S, Dong C. A multifunctional SN38-conjugated nanosystem for defeating myelosuppression and diarrhea induced by irinotecan in esophageal cancer. Nanoscale 2020;12:21234-47. [PMID: 33063070 DOI: 10.1039/d0nr06266a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ashford MB, England RM, Akhtar N. Highway to Success—Developing Advanced Polymer Therapeutics. Adv Therap 2021;4:2000285. [DOI: 10.1002/adtp.202000285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, Parker J, Giannis M, Hill KJ, Gibbons FD, Hennessy EJ, Kemmitt P, Harmer AR, Gales S, Purbrick S, Redmond S, Skinner M, Graham L, Secrist JP, Schuller AG, Wen S, Adam A, Reimer C, Cidado J, Wild M, Gangl E, Fawell SE, Saeh J, Davies BR, Owen DJ, Ashford MB. Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol 2021;4:112. [PMID: 33495510 DOI: 10.1038/s42003-020-01631-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
8 Taresco V, Abelha TF, Cavanagh RJ, Vasey CE, Anane‐adjei AB, Pearce AK, Monteiro PF, Spriggs KA, Clarke P, Ritchie A, Martin S, Rahman R, Grabowska AM, Ashford MB, Alexander C. Functionalized Block Co‐Polymer Pro‐Drug Nanoparticles with Anti‐Cancer Efficacy in 3D Spheroids and in an Orthotopic Triple Negative Breast Cancer Model. Adv Therap 2021;4:2000103. [DOI: 10.1002/adtp.202000103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 England RM, Moss JI, Gunnarsson A, Parker JS, Ashford MB. Synthesis and Characterization of Dendrimer-Based Polysarcosine Star Polymers: Well-Defined, Versatile Platforms Designed for Drug-Delivery Applications. Biomacromolecules 2020;21:3332-41. [PMID: 32672451 DOI: 10.1021/acs.biomac.0c00768] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
10 Carvalho MR, Reis RL, Oliveira JM. Dendrimer nanoparticles for colorectal cancer applications. J Mater Chem B 2020;8:1128-38. [PMID: 31971528 DOI: 10.1039/c9tb02289a] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
11 Sodano F, Cavanagh RJ, Pearce AK, Lazzarato L, Rolando B, Fraix A, Abelha TF, Vasey CE, Alexander C, Taresco V, Sortino S. Enhancing doxorubicin anticancer activity with a novel polymeric platform photoreleasing nitric oxide. Biomater Sci 2020;8:1329-44. [DOI: 10.1039/c9bm01644a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Si J, Zhao X, Gao S, Huang D, Sui M. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin. International Journal of Pharmaceutics 2019;568:118499. [DOI: 10.1016/j.ijpharm.2019.118499] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
13 Tulli LG, Miranda D, Lee CC, Sullivan Y, Grotzfeld R, Hollingworth G, Kneuer R, Karpov AS. Modular synthesis and modification of novel bifunctional dendrons. Org Biomol Chem 2019;17:2906-12. [DOI: 10.1039/c8ob02988a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 England RM, Moss JI, Hill KJ, Elvevold K, Smedsrød B, Ashford MB. Evaluating liver uptake and distribution of different poly(2-methyl-2-oxazoline) modified lysine dendrimers following intravenous administration. Biomater Sci 2019;7:3418-24. [DOI: 10.1039/c9bm00385a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Hegde N, Velingkar V, Prabhakar B. An Update on Design and Pharmacology of Dendritic Poly(l-lysine). Int J Pept Res Ther 2019;25:1539-62. [DOI: 10.1007/s10989-018-9798-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Lorson T, Lübtow MM, Wegener E, Haider MS, Borova S, Nahm D, Jordan R, Sokolski-papkov M, Kabanov AV, Luxenhofer R. Poly(2-oxazoline)s based biomaterials: A comprehensive and critical update. Biomaterials 2018;178:204-80. [DOI: 10.1016/j.biomaterials.2018.05.022] [Cited by in Crossref: 200] [Cited by in F6Publishing: 204] [Article Influence: 40.0] [Reference Citation Analysis]
17 Einafshar E, Asl AH, Nia AH, Mohammadi M, Malekzadeh A, Ramezani M. New cyclodextrin-based nanocarriers for drug delivery and phototherapy using an irinotecan metabolite. Carbohydrate Polymers 2018;194:103-10. [DOI: 10.1016/j.carbpol.2018.03.102] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
18 Christensen JB. Dendrimers-Based Nanoparticles for Cancer Therapy and Bioimaging. Nanooncology 2018. [DOI: 10.1007/978-3-319-89878-0_8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Yang X, Xue X, Luo Y, Lin TY, Zhang H, Lac D, Xiao K, He Y, Jia B, Lam KS, Li Y. Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy. J Control Release 2017;261:297-306. [PMID: 28700898 DOI: 10.1016/j.jconrel.2017.07.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
20 Hartlieb M, Floyd T, Cook AB, Sanchez-cano C, Catrouillet S, Burns JA, Perrier S. Well-defined hyperstar copolymers based on a thiol–yne hyperbranched core and a poly(2-oxazoline) shell for biomedical applications. Polym Chem 2017;8:2041-54. [DOI: 10.1039/c7py00303j] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]